Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	5.37K -99.4%
Revenue (ttm)	386.00K -95.6%
Net Income	-97.82M
EPS	-2.66
Shares Out	26.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,911
Open	0.0005
Previous Close	0.0002
Day's Range	0.0002 - 0.0005
52-Week Range	0.000001 - 0.0400
Beta	1.26
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 2, 2026

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYRS

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.